SMPD1 and anterior segment dysgenesis: Statement 25: Olipudase alfa, an enzyme replacement therapy (ERT) using human recombinant acid sphingomyelinase, is indicated as a disease-modifying enzyme replacement therapy for the long-term treatment of non-central nervous system (CNS) manifestations of ASMD.